Won Kyung Cho1, Doo Ho Choi2, Jieun Lee3, Won Park1, Yong Bae Kim4, Chang-Ok Suh4, Kyung Hwan Shin5, Seung Hyuck Jeon5, Kyubo Kim6, Kyung Ran Park7, Jin Hee Kim8, Sung Ja Ahn9, Won Sup Yoon10, Dae Sik Yang11, Juree Kim12, Jong Hoon Lee13, Ji Woon Yea14. 1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: doho.choi@samsung.com. 3. Graduate School of Korea University, Seoul, Republic of Korea. 4. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea. 5. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea. 6. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Republic of Korea. 7. Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Republic of Korea. 8. Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea. 9. Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Republic of Korea. 10. Department of Radiation Oncology, Ansan Hospital, Korea University, Ansan, Republic of Korea. 11. Department of Radiation Oncology, Guro Hospital, Korea University, Seoul, Republic of Korea. 12. Department of Radiation Oncology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Seoul, Republic of Korea. 13. Department of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Republic of Korea. 14. Department of Radiation Oncology, Yeungnam University Medical Center, Daegu, Republic of Korea.
Abstract
PURPOSE: Information on tubular carcinoma (TC) of breast is limited due to its rarity. A multi-institutional study was performed to investigate the prognosis and failure patterns of TC compared to invasive ductal carcinoma (IDC). MATERIALS AND METHODS: We collected retrospective data on 205 patients with TC from eleven institutions. For each TC case, 3 cases with IDC were matched according to similar size, t-stage, and n-stage from the same institution. Patterns of failure, disease free survival (DFS) and overall survival (OS) were assessed and compared between the groups. RESULTS: DFS at 5 years was 98.8% and 97.3% and OS at 5 years was 99.5% and 99.6% in TC and IDC, respectively. Among the patients with TC, 5 patients (2.4%) developed contralateral breast cancer, while 3 patients (0.5%) presented with contralateral breast cancer in patients with IDC. CONCLUSIONS: The TC of breast presents an excellent prognosis, but the contralateral breast cancer tends to be more frequently observed compared to IDC in Korean women.
PURPOSE: Information on tubular carcinoma (TC) of breast is limited due to its rarity. A multi-institutional study was performed to investigate the prognosis and failure patterns of TC compared to invasive ductal carcinoma (IDC). MATERIALS AND METHODS: We collected retrospective data on 205 patients with TC from eleven institutions. For each TC case, 3 cases with IDC were matched according to similar size, t-stage, and n-stage from the same institution. Patterns of failure, disease free survival (DFS) and overall survival (OS) were assessed and compared between the groups. RESULTS: DFS at 5 years was 98.8% and 97.3% and OS at 5 years was 99.5% and 99.6% in TC and IDC, respectively. Among the patients with TC, 5 patients (2.4%) developed contralateral breast cancer, while 3 patients (0.5%) presented with contralateral breast cancer in patients with IDC. CONCLUSIONS: The TC of breast presents an excellent prognosis, but the contralateral breast cancer tends to be more frequently observed compared to IDC in Korean women.